摘要
目的观察重组人血小板生成素（rhTPO）联合大剂量地塞米松治疗原发性血小板减少症（ITP）的疗效及安全性。方法回顾性分析2009年1月至2015年12月我院接受rhTPO治疗的34例成年ITP患者临床资料与同期接受大剂量地塞米松治疗的37例患者进行对比观察。结果全部71例ITP患者中男28例，女43例，中位年龄28岁（18～64岁），新诊断ITP患者35例，持续性ITP20例，慢性ITP16例；重症ITP（PLT〈10×10^9／L）42例。rhTPO组与对照组总有效率差异无统计学意义（P〉0．05）。rhTPO组与对照组新诊断ITP、持续性及慢性ITP患者总有效率差异均无统计学意义（P〉0．05）。rhTPO组与对照组治疗后PLT峰值、PLT〉30×10^9／L维持7天以上病例数差异均无统计学意义（P〉0．05）。两组患者均无明显不良反应发生。结论rhTPO联合地塞米松治疗ITP的疗效与单药地塞米松相当，安全性较好。
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin （rhTPO） combined with glucocorticoid in treatment of severe immune thrombocytopenia（ITP）. Methods The clinical characteristics of 34 ITP patients who received rhTPO and glucocorticoid therapy from January 2009 to December 2015 were retrospectively analyzed（as rhTP0 group）. During the same time another 37 ITP patients who received glucocorticoid therapy only were selected as control group. The treatment outcomes were evaluated. Results A total of 71 cases of pediatric ITP. 28 males and 43 females with a median age 28 （18-64）years were enrolled,including35 cases of newly disgnosed ITP. 20 cases of persistent ITP and 16 cases of chronic ITP. Of them,42 cases of whom were severe 1TP （PLT〈10×10^9/L）. The total response rate had no statistically significant difference between the rhTPO group and the control group（P〉0.05） ,neither in newly ITP persistent and chronic ITP（P〉0.05）. The median maximum peak of platelet counts and the time of the platelet counts〉30 × 10^9/L had no statistically significant differences in rhTPO group compared with the control group. No severe adverse effects were observed in both groups. Conclusion For ITP rhTPO with glucocorticoid has a similar outcomes with glucocortico＇id, and it is an effective and safe treatment option.
出处
《检验医学》
CAS
2016年第B09期5-6,共2页
Laboratory Medicine
